TITLE

GBC BIOTECH PRESENTS NEW DATA ON EFFICACY OF SATRAPLATIN

PUB. DATE
April 2004
SOURCE
Worldwide Biotech;Apr2004, Vol. 16 Issue 4, p8
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the presentation of in vitro data by GPC Biotech AG on the efficacy of Satraplatin in tumor cells resistant to both TAXOTERE and TAXOL, chemotherapeutic agents in the treatment of human cancers. Focus of the study; Primary known mechanisms of resistance to the taxane family of compounds; Medical administration of Satraplatin.
ACCESSION #
12714980

 

Related Articles

  • GPC Biotech expands Satraplatin phase III trial.  // PharmaWatch: Cancer;March 2004, Vol. 3 Issue 3, p13 

    Reports that GPC Biotech received a Scientific Advice letter from the European Agency for the Evaluation of Medicinal Products, enabling it to proceed with its registrational plans in Europe using the Satraplatin and Prednisone Against Refractory Cancer trial. Trial evaluation of Satrapaltin...

  • High Hopes For a Prostate Cancer Drug. Gaudio, Thomas // njbiz;5/28/2007, Vol. 20 Issue 22, p3 

    The article reports on satraplatin, a drug for prostate cancer developed by GPC Biotech AG that is being reviewed by the U.S. Food and Drug Administration (FDA). It states that the drug would be used with prednisone to treat patients with hormone refractory prostate cancer (HRPC). The firm is...

  • Spectrum and GPC prostate cancer drug shows promise in vitro.  // PharmaWatch: Cancer;January 2005, Vol. 4 Issue 1, p18 

    Reports that development partners Spectrum Pharmaceuticals Inc. and GPC Biotech AG have presented data on the effect of satraplatin on prostate cancer cell lines. Reduction in prostate-specific antigen (PSA) expression; Tumor cell death.

  • GPC Biotech expands Satraplatin phase III trial.  // PharmaWatch: Biotechnology;March 2004, Vol. 3 Issue 3, p5 

    Reports on the expansion of satraplatin phase III trial of GPC Biotech AG in Europe. Demonstration of the safety and efficacy of medicinal products; Completion of a Special Protocol Assessment by the Food abd Drug Administration; Treatment of patients with hormone-refractory prostate cancer.

  • GPC Biotech expands testing of cancer treatment.  // PharmaWatch: Biotechnology;October 2004, Vol. 3 Issue 10, p6 

    The article presents information about GPC Biotech AG, which has initiated a clinical study to evaluate the combination of its lead drug candidate, satraplatin, in combination with radiation therapy in patients with locally advanced non-small cell lung cancer. The first phase of the study is...

  • GPC Biotech presents new data supporting efficacy of anticancer monoclonal antibody.  // PharmaWatch: Biotechnology;October 2003, Vol. 2 Issue 10, p8 

    Reports on data presented by GPC Biotech AG on its anticancer monoclonal antibody, 1D09C3. Evaluation of the antibody in combination with Rituxan in an in vivo non-Hodgkin's lymphoma model; Synergistic effect of the two antibodies; Comparison of the cure rate of the combination therapy with...

  • Spectrum's prostate anticancer drug candidate granted fast track designation.  // PharmaWatch: Cancer;November 2003, Vol. 2 Issue 11, p22 

    Reports that the United States Food and Drug Administration has granted Spectrum Pharmaceuticals Inc. and GPC Biotech AG fast track designation for satraplatin as a second-line treatment for hormone-refractory prostate cancer. Clinical trial evaluating satraplatin plus prednisone versus...

  • GPC Biotech invests $2 million on launch of phase III trial of Satraplatin.  // PharmaWatch: Cancer;November 2003, Vol. 2 Issue 11, p22 

    Reports that Spectrum Pharmaceuticals Inc. has received payment from GPC Biotech AG after the treatment of the first patient in the satraplatin phase III hormone-refractory prostate cancer trial. Amount received by Spectrum; Spectrum's plans to expand its generic drug portfolio; Terms of the...

  • Preclinical Evaluation of New Taxoids. Bissery, M.-C. // Current Pharmaceutical Design;Sep2001, Vol. 7 Issue 13, p1251 

    Paclitaxel and docetaxel are two key molecules in the treatment of a variety of cancers with major impact in the treatment of breast, lung and ovarian cancers. A number of taxoids have then been synthesized in an effort to improve some of the features of the existing drugs. Although the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics